Renee D. Gala received $19.2M in total compensation as President CEO and Director of Jazz Pharmaceuticals plc in FY2025. The largest component was $16.1M in stock awards. Source: SEC DEF 14A.
In fiscal year 2025, Renee D. Gala, President CEO and Director of Jazz Pharmaceuticals plc (JAZZ), received total compensation of $19.2 million.
Renee D. Gala's compensation breakdown includes: base salary of $1.0 million, stock awards valued at $16.1 million, non-equity incentive compensation of $2.0 million, and other compensation of $30K.
Jazz Pharmaceuticals plc's top 5 named executive officers received combined total compensation of $47.7 million in fiscal year 2025.
The named executive officers disclosed in Jazz Pharmaceuticals plc's 2025 proxy statement are:Renee D. Gala (President CEO and Director) with total compensation of $19.2 million, Robert Iannone (M.D., M.S.C.E Executive Vice President, Global Head of R&D) with total compensation of $8.7 million, Philip L. Johnson (Executive Vice President and CFO) with total compensation of $7.5 million, Neena M. Patil (Executive Vice President and Chief Legal Officer) with total compensation of $6.3 million, and Samantha Pearce (Executive Vice President Chief Commercial Officer) with total compensation of $6.1 million.
Renee D. Gala, President CEO and Director of Jazz Pharmaceuticals plc (JAZZ), received $19,151,558 in total compensation for FY2025. Stock awards of $16,138,433 were the largest component. Figures come from Jazz Pharmaceuticals plc's DEF 14A 0001232524-26-000029 filed 8 Jun 2026.
Source Filing
Executive Record
Renee D. Gala
President CEO and Director
Reported Pay
$19.2MSummary compensation table total · FY2025
Read the board's pay decision against shareholder returns and current filing context.
Jazz Pharmaceuticals plc (JAZZ) — Key Facts
Last updated Sep 4, 2026 · DEF 14A filed Jun 8, 2026
| CEO | Renee D. Gala, President CEO and Director |
|---|---|
| Fiscal year | FY2025 |
| Total compensation | $19.2M |
| Base salary | $1.0M |
| Stock awards | $16.1M |
| Other compensation | $30K |
| Source | DEF 14A, 2026-06-08 |
Renee D. Gala, the President CEO and Director of Jazz Pharmaceuticals plc, received total compensation of $19,151,558 in fiscal year 2025. This includes base salary of $1,003,269 and stock awards valued at $16,138,433. Figures come from Jazz Pharmaceuticals plc's DEF 14A 0001232524-26-000029 filed 8 Jun 2026.
Renee D. Gala's base salary at Jazz Pharmaceuticals plc is $1,003,269 per year as of fiscal year 2025. However, total compensation including stock awards, bonuses, and other benefits is $19,151,558. Figures come from Jazz Pharmaceuticals plc's DEF 14A 0001232524-26-000029 filed 8 Jun 2026.
Jazz Pharmaceuticals plc's CEO, Renee D. Gala, earned $19,151,558 in total compensation for fiscal year 2025. The majority of this compensation comes from stock awards ($16,138,433) rather than base salary ($1,003,269). Figures come from Jazz Pharmaceuticals plc's DEF 14A 0001232524-26-000029 filed 8 Jun 2026.
Reading filings for JAZZ...
Reading the latest proxy statement
Calculating CEO-to-worker ratio
Checking insider sales and trading plans